0
Pulmonary Vascular Disease |

Hemodynamic Effects of First-Line Bosentan and Sildenafil Combination Therapy for Pulmonary Arterial Hypertension

Jason Weatherald, MD; Doug Helmersen, MD; Mitesh Thakrar, MD; Naushad Hirani, MD
Author and Funding Information

Division of Respirology, Department of Medicine, University of Calgary, Calgary, AB, Canada


Chest. 2013;144(4_MeetingAbstracts):868A. doi:10.1378/chest.1702940
Text Size: A A A
Published online

Abstract

SESSION TITLE: DVT/PE/Pulmonary Hypertension Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 30, 2013 at 01:30 PM - 02:30 PM

PURPOSE: Sequential combination therapy for pulmonary arterial hypertension (PAH) is standard practice, but data on the safety and efficacy of initial combination therapy in PAH are limited. No studies have evaluated the use of two oral first-line agents that target distinct pathobiologic pathways in PAH.

METHODS: We conducted a prospective, single-centre, open label study evaluating first-line combination treatment with bosentan and sildenafil in patients with newly-diagnosed PAH. We compared functional, echocardiographic and hemodynamic measurements at baseline, 4 months and 12 months.

RESULTS: Thirteen patients with idiopathic (n=6) or connective tissue disease-related PAH (n=7) were enrolled between November, 2009 and January, 2012, and data from 12 patients were available for analysis. All patients were functional class III at enrollment. Two patients experienced drug related hepatotoxicity. Impressive hemodynamic improvements were observed at 4 months, and improvements persisted and even continued in some patients up to one year. Mean pulmonary artery pressure fell at 4 months (51.1±9 mmHg vs. 43.8±14.5 mmHg, p=0.02) and remained low at 12 months (53.7±9.5 vs 39.5±11.8 mmHg, p=0.04). Cardiac index increased by 50% at 4 months (2.0±0.6 vs 3.0±0.8 L/min/m2, p< 0.01) and 63% at 12 months (1.9±0.6 vs 3.1±0.8 L/min/m2, p<0.01). Pulmonary vascular resistance decreased by 49% at 4 months (14.2±9.1 vs 7.4±4.7 Wood Units, p=0.02) and 55% at 12 months (16.5±11.2 vs 7.5±5.3, p=0.01). The magnitude of the observed hemodynamic improvements was dramatic in comparison to the experience with a bosentan or sildenafil monotherapy strategy. Functional and echocardiographic parameters also improved in concert with the hemodynamics: 6-minute walk distance (6MWD) improved from 274±89.4m to 315±126.3 at 4 months (p=0.11) and to 396.5±109.7 at 12 months (p=0.01), as did tricuspid annular plane systolic excursion (TAPSE) (1.5±0.5 cm vs 1.9±0.3 cm and 2.0±0.3 cm, p<0.01)

CONCLUSIONS: First-line oral combination therapy with bosentan and sildenafil was associated with impressive improvements in hemodynamics at 4 months, which persisted at one year.

CLINICAL IMPLICATIONS: The strategy of combining oral PAH targeted therapies as a first-line approach may result in greater and more durable improvements in hemodynamics than those seen with an initial monotherapy approach. Further analysis of this cohort and larger randomized studies are needed to evaluate this strategy in more detail. (Clinicaltrials.gov id NCT01247116)

DISCLOSURE: Doug Helmersen: Grant monies (from industry related sources): Have received research funding from Bayer, Gilead, and Novartis and Pfizer, Consultant fee, speaker bureau, advisory committee, etc.: Have received consultant and speaker fees from Actelion Naushad Hirani: Grant monies (from industry related sources): Have received research funding from Actelion, United Therapeutics, Glaxo-Smith-Kline, and Gilead., Consultant fee, speaker bureau, advisory committee, etc.: Have received consultant and speaker fees from Actelion The following authors have nothing to disclose: Jason Weatherald, Mitesh Thakrar

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543